Endomag expands life-saving cancer technology
Endomag, the market leader for seed localisation in Europe, has received an extended indication for the long-term use of the Magseed® magnetic marker in any soft tissue.
The Magseed® marker has already helped tens of thousands of women to benefit from more accurate marking and removal of breast tumours.
This new indication makes the Magseed® marker the first and only localisation seed in Europe that physicians can place days, weeks or even months ahead of surgery to mark any cancer site for accurate removal.
The Magseed® marker is a tiny seed made from surgical grade steel. It is placed in tissue to mark tumours before surgery to help the surgeon accurately locate the cancer in the operating room and remove it in one piece. Once placed, it cannot be dislodged or damaged and is detected by the Sentimag® probe with millimetre precision.
Endomag CEO Eric Mayes said: “Ever since we launched the Magseed® marker we have been asked by European physicians if they can use it to mark a variety of different cancer sites in the body, which also require a longer implantation than the 30 days we had in Europe.
“We received this expanded indication from the FDA last year and I’m delighted that Endomag is the first to offer this same level of targeted treatment to European cancer patients.”
Thanks to the rapid progression in breast cancer treatment more women are receiving chemotherapy before surgery to help shrink their tumour. However, treating the tumour so early makes it difficult to determine if the cancer has spread beyond the breast when the patient comes to surgery.
With this new indication, the Magseed® marker can now be used to mark suspicious lymph nodes before chemotherapy and in conjunction with Endomag’s lymphatic mapping agent, Magtrace® will allow the surgeon to perform a more targeted dissection and determine if the cancer has spread.
Results from two independent studies conducted by Dr Abigail Caudle from MD Anderson Cancer Center, Houston and Dr Heather Greenwood, University of California, San Francisco, demonstrated the ease and accuracy of marking positive lymph nodes with the Magseed® marker with 100 per cent retrieval success.
Dr Caudle said: “We have been using Magseed for two years and have performed over a thousand surgeries with the technology. The ability to mark lymph nodes and ensure we remove the cancerous node to examine them closely is a huge advantage for patients because we spare them extensive and unnecessary axillary surgery.”
In the United States the Magseed® marker received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the same indication in 2018.
Many of the world’s leading physicians and hospitals use Endomag’s technologies to help women with breast cancer avoid surgery when it isn’t needed and experience better outcomes when it is.
The company was founded in 2007 when two professors based at University College London (UCL) and the University of Houston realised that magnetics might be able to improve the existing standard of cancer care.
Years of painstaking research led them to successfully develop a magnetic sensor capable of detecting one millionth of the Earth’s magnetic field, the Sentimag® probe.
The Sentimag® probe works like a metal detector, which when placed near the skin’s surface can detect Endomag’s magnetic seed (Magseed®) or liquid tracer (Magtrace®), used in tissue localisation and sentinel node biopsy procedures, respectively.
To this day the Sentimag® system has been used in over 75,000 breast cancer procedures at over 500 hospitals in more than 35 countries.
Endomag is a global company headquartered in Cambridge UK, with an office in Austin, Texas.